Systemic immunomodulating therapies for epidermal necrolysis (Stevens-Johnson syndrome/toxic epidermal necrolysis): A systematic review and meta-analysis

表皮坏死松解症(史蒂文斯-约翰逊综合征/中毒性表皮坏死松解症)的系统性免疫调节疗法:系统评价和荟萃分析

阅读:1

Abstract

BACKGROUND AND OBJECTIVES: Epidermal necrolysis is a rare but severe cutaneous reaction with high mortality. Limited evidence exists regarding the efficacy of systemic immunomodulatory therapies (SITs). Our systematic review aimed to compare SITs with supportive care or one another. PATIENTS AND METHODS: Randomized controlled trials and controlled observational studies (≥ 5 patients of all ages per arm) using the international consensus classification for EN (Bastuji-Garin, 1993) with no significant baseline differences were included. We searched MEDLINE, Embase, and Cochrane CENTRAL (January 1, 1993-January 22, 2024). Two reviewers independently extracted study and outcome data. A random-effects meta-analysis was performed. RESULTS: The main outcome was mortality. Secondary outcomes included hospital stay duration, time to complete reepithelialization, complications, and sequelae. 43 studies with 58 treatment comparisons were analyzed. Cyclosporine was superior to IVIG regarding mortality (RR 0.18, 95% CI 0.05-0.58), and corticosteroids plus IVIG reduced serious complications compared to corticosteroids alone (sepsis, RR 0.77, 95% CI 0.31-0.77). Compared to supportive care, only etanercept showed a significant mortality benefit (RR 0.32, 95% CI 0.11-0.93; GRADE: imprecision/unclear clinical importance). CONCLUSIONS: There is no clear evidence of the superiority of SITs over supportive care, which remains the primary treatment for EN.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。